These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23276932)

  • 21. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy in colorectal cancer: current status and future challenges.
    Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
    Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].
    Tournigand C; Bengrine-Lefevre L
    Rev Med Interne; 2009 May; 30(5):411-5. PubMed ID: 19231039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
    N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular alterations and biomarkers in colorectal cancer.
    Grady WM; Pritchard CC
    Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular target therapy and chemotherapy for advanced colorectal cancer].
    Nakashima K; Yamazaki K; Boku N
    Gan To Kagaku Ryoho; 2008 May; 35(5):725-30. PubMed ID: 18487907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of anti-EGFR target therapy in colorectal carcinoma.
    Enrique AA; Gema PC; Jeronimo JC; Auxiliadora GE
    Front Biosci (Elite Ed); 2012 Jan; 4(1):12-22. PubMed ID: 22201852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
    Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
    Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of epidermal growth factor inhibitors.
    Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
    Starling N; Cunningham D
    Curr Opin Oncol; 2004 Jul; 16(4):385-90. PubMed ID: 15187895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.